Literature DB >> 10023450

The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication.

R L Touraine1, H Ishii-Morita, W J Ramsey, R M Blaese.   

Abstract

The bystander effect (BSE) is an interesting and important property of the herpes thymidine kinase/ganciclovir (hTK/GCV) system of gene therapy for cancer. With the BSE, not only are the hTK expressing cells killed upon ganciclovir (GCV) exposure but also neighboring wild-type tumor cells. On testing a large number of tumor cell lines in vitro, a wide range of sensitivity to bystander killing was found. Since transfer of toxic GCV metabolites from hTK-modified to wild-type tumor cells via gap junctions (GJ) seemed to be a likely mechanism of the BSE, we tested GJ function in these various tumors with a dye transfer technique and pharmacological agents known to affect GJ communication. We confirmed that mixtures of tumor cell resistant to the BSE did not show dye transfer from cell to cell while bystander-sensitive tumor cells did. Dieldrin, a drug known to decrease GJ communication, diminished dye transfer and also inhibited the BSE. Forskolin, an upregulator of cAMP did increase GJ, but directly inhibited hTK and therefore its effect on BSE could not be determined. We conclude that these observations further support port the concept that functional GJ play an important role in the BSE and further suggest that pharmacological manipulation of GJ may influence the outcome of cancer therapy with hTK/GCV.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10023450     DOI: 10.1038/sj.gt.3300784

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  22 in total

Review 1.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.

Authors:  Chien-Kuo Tai; Wei Jun Wang; Thomas C Chen; Noriyuki Kasahara
Journal:  Mol Ther       Date:  2005-11       Impact factor: 11.454

Review 3.  Introduction to the background, principles, and state of the art in suicide gene therapy.

Authors:  Ion Niculescu-Duvaz; Caroline J Springer
Journal:  Mol Biotechnol       Date:  2005-05       Impact factor: 2.695

Review 4.  Gap junctions and cancer: communicating for 50 years.

Authors:  Trond Aasen; Marc Mesnil; Christian C Naus; Paul D Lampe; Dale W Laird
Journal:  Nat Rev Cancer       Date:  2016-10-21       Impact factor: 60.716

5.  Bioengineered viral vectors for targeting and killing prostate cancer cells.

Authors:  Kai-xin Zhang; William Jia; Paul S Rennie
Journal:  Bioeng Bugs       Date:  2010-01-04

6.  Experimental study of thymidine kinase gene therapy of neuroblastoma in vitro and in vivo.

Authors:  Xun Bi; Jing-Zhe Zhang
Journal:  Pediatr Surg Int       Date:  2003-07-05       Impact factor: 1.827

Review 7.  Prodrugs and prodrug-activated systems in gene therapy.

Authors:  Semira Sheikh; Daniel Ernst; Armand Keating
Journal:  Mol Ther       Date:  2021-04-06       Impact factor: 11.454

8.  Exogenous wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma cells.

Authors:  Qiang Huang; Peiyu Pu; Zhibo Xia; Yongping You
Journal:  J Neurooncol       Date:  2006-11-11       Impact factor: 4.506

9.  A tunable dual-promoter integrator for targeting of cancer cells.

Authors:  Lior Nissim; Roy H Bar-Ziv
Journal:  Mol Syst Biol       Date:  2010-12-21       Impact factor: 11.429

10.  Bystander-mediated regression of murine neuroblastoma via retroviral transfer of the HSV-TK gene.

Authors:  Hyun-Sang Cho; Hye-Ran Lee; Moon Kyu Kim
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.